Leptomycin B (LMB) and/or its derivatives, which can efficiently inhibit nuclear export by specifically inhibiting chromosome region maintenance 1 (CRM1), has been recognized as a novel class of cancer therapeutics [8], [9], [10], [11], [12]. This evidence concerns the gene XPO1 and cancer.